Clinical trials: Prostate Cancer Metastatic, open to volunteers
Non-metastatic Castration-resistant Prostate Cancer
A Study to Learn More About How Safe Darolutamide is and How Well it Works Under Real World Conditions When Taken in Addition to Standard Androgen Deprivation Therapy (ADT) in Indian Participants With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)
Researchers are looking for a better way to treat men who have non-metastatic castration-resistant prostate cancer (nmCRPC). This is a type of cancer of the prostate that has not yet spread to other parts of the body and that…
- Trial name
- NCT05348876
- Testing
- Darolutamide (Nubeqa, BAY1841788)
- Where
- 15 sites in India
- Volunteers
- 50 people
- Sponsor
- Bayer
Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma
Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial
This phase II trial compares giving estrogen with an androgen receptor signaling inhibitor to standard of care luteinizing hormone-releasing hormone (LHRH) analogues with an androgen receptor signaling inhibitor for improving…
- Conditions
- Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
- Trial name
- NCT07466498
- Testing
- Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Fred Hutchinson Cancer Center
Oligo-metastatic Prostate Carcinoma
Radiotherapy for Prostate and Oligo-metastatic Lesions in Patients With Low-burden Oligo-metastatic Prostate Cancer
The existing large prospective study demonstrates the benefits of primary radiotherapy in patients with low-volume oligo-metastatic prostate cancer (OMPC), and there is also more evidence of the benefits of local…
- Trial name
- NCT06198387
- Testing
- hormone and RT, ADT combined with abiraterone
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Changhai Hospital
Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other…
- Conditions
- Castration Levels of Testosterone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT03678025
- Testing
- Abiraterone, Bicalutamide, Degarelix
- Where
- 338 sites in United States, Chile and 3 more
- Volunteers
- 1,273 people
- Sponsor
- SWOG Cancer Research Network
Castration Resistant Metastatic Prostate Cancer, Prostate Cancer
A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is a Phase 1b, multi-center, open-label study to evaluate the safety, tolerability, dosimetry, and pharmacokinetics (PK) of [64Cu]Cu-AKY-2519 and/or [225Ac]Ac-AKY-2519, as well as the preliminary anti-tumor activity of…
- Conditions
- Castration Resistant Metastatic Prostate Cancer, Prostate Cancer, mCRPC (Metastatic Castration-resistant Prostate Cancer), mCRPC
- Trial name
- BActinium-1 (NCT07581184)
- Testing
- [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging)
- Where
- 8 sites in United States
- Volunteers
- 138 people
- Sponsor
- Aktis Oncology, Inc.
Prostate Cancer Metastatic Disease
Efficacy and Tolerability of Low-Dose Enzalutamide in Prostate Cancer
Prostate cancer is the most common cancer in men in the United States and the second leading cause of cancer-related mortality in males.
- Trial name
- LODE (NCT06718647)
- Where
- Italy
- Volunteers
- 150 people
- Sponsor
- Monica Boitano
mCRPC
Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC）
This study is to evaluate the safety, and preliminary antitumor activity of TYK-00540 combined with Enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) that have failed novel endocrine therapy
- Trial name
- NCT07104643
- Testing
- TYK-00540, Enzalutamide
- Where
- China
- Volunteers
- 48 people
- Sponsor
- TYK Medicines, Inc
Metastatic Castration-resistant Prostatic Neoplasms
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in…
- Trial name
- KLK2-comPAS (NCT07164443)
- Testing
- Pasritamig, Best Supportive Care (BSC), JNJ-87189401
- Where
- 176 sites in United States, Australia and 15 more
- Volunteers
- 1,203 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
The goal of this clinical trial is to learn if fezolinetant can treat hot flashes (vasomotor symptoms) in men with prostate cancer undergoing androgen deprivation therapy.
- Conditions
- Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent
- Trial name
- Fezo-ADT (NCT06957691)
- Testing
- fezolinetant - reference formulation
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shehzad Basaria, M.D.
Metastatic Castration-resistant Prostate Cancer
Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC
The purpose of this study is to evaluate whether high-dose testosterone followed by targeted radioligand therapy (TRT) is effective in treating metastatic castration resistant prostate cancer.
- Trial name
- NCT07476001
- Testing
- Testosterone cypionate (Tc), ADT with Luteinizing hormone-releasing hormone (LHRH) analog, PSMA-617
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Solid Tumor, Recurrent Solid Tumor
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer.
- Conditions
- Metastatic Solid Tumor, Recurrent Solid Tumor, Advanced Solid Tumor, Urinary Bladder Neoplasm
- Trial name
- NEXUS-01 (NCT06465069)
- Testing
- LY4052031, Pembrolizumab
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Advanced Unresectable, Metastatic
Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors
This is a multicenter, open-label, Phase 1/2 master protocol evaluating autologous dual-target CAR-T cell therapy in adults with advanced solid cancers.
- Trial name
- SELECT-2CAR (NCT07523529)
- Testing
- Autologous dual-target CAR-T cells selected from the predefined target library., Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 72 people
- Sponsor
- Beijing Biotech
Prostate Cancer
Apa/Enza-short Study: Shorter Treatment With Androgen Receptor Pathway Inhibitor in Patients With Low-volume Metastatic Castration-sensitive Prostate Cancer
The goal of this clinical trial is to evaluate the outcomes of a shorter treatment duration (12 months) with an androgen receptor pathway inhibitor (ARPI), in this study Apalutamide or Enzalutamide, in patients with low-volume…
- Trial name
- Apa/Enza-short (NCT07260435)
- Testing
- ADT plus only 12 months of ARPI, ADT plus continued ARPI
- Where
- 26 sites in Netherlands
- Volunteers
- 400 people
- Sponsor
- Nick Beije
Metastatic Prostate Cancer
PRostate Cancer Plasma Integrative Multi-modal Evaluation
The study aims to develop PRIME (PRostate cancer plasma Integrative Multi-modal Evaluation) liquid biopsy test and to implement its use to query prospectively collected samples in advanced prostate cancer (PCa) clinical trials…
- Trial name
- PRIME (NCT06981377)
- Testing
- Analysis of cell free DNA, and extracellular vesicles (EVs) and EV-associated molecular components (including RNA, DNA, proteins)
- Where
- 4 sites in Italy
- Volunteers
- 800 people
- Sponsor
- Santa Chiara Hospital
Castration-resistant Prostate Cancer
A Study of BL-B01D1 Combination Therapy in Patients With Metastatic Castration-resistant Prostate Cancer
This study will first conduct a phase II clinical study, and on the basis of the phase II clinical study, subsequent clinical research will be carried out.
- Trial name
- NCT07641855
- Testing
- BL-B01D1, Abiraterone, Olaparib
- Where
- 2 sites in China
- Volunteers
- 180 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Prostate Cancer
Sequential Study of 225Ac-LNC1011 in the Treatment of Metastatic Castration-Resistant Prostate Cancer
PSMA is an ideal target for the precise diagnosis and treatment of prostate cancer. LNC1011 is a novel albumin-binding PSMA-targeted compound.
- Trial name
- NCT07363486
- Testing
- 225Ac-LNC1011
- Where
- China
- Volunteers
- 9 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Prostate Cancer Castration-resistant Prostate Cancer
Study of Allogeneic Anti-PSMA CAR-NK Cell for Metastatic Castration-Resistant Prostate Cancer
At present, no cell drug with an indication for mCRPC has been approved for marketing in China, and there is no scholar to fight against it PSMA-CAR-NK cell therapy CRPC was reported in a study.
- Trial name
- NCT07156045
- Testing
- anti-PSMA CAR-NK
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
mCRPC
Efficacy and Safety of Disitamab Vedotin Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer：a Phase II Study
This is an open-label，prospective，single-arm，phase 2 trial aims to evaluate the efficacy and safety of disitamab vedotin combined with abiraterone in patients with metastatic castration-resistant prostate cancer.
- Trial name
- NCT07093866
- Testing
- Disitamab Vedotin (RC48), Abiraterone + prednisone
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Metastatic Hormone-Sensitive Prostate Cancer
A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.
This study plans to enroll patients with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) and conduct a prospective, single-center, observational study.
- Trial name
- NCT07795177
- Testing
- ADT plus abiraterone or other ARPIs（apalutamide, enzalutamide, rezvilutamide, darolutamide)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Anhui Medical University
Castrate Resistance Prostate Cancer, OligoProgressive Metastatic Disease
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy…
- Trial name
- SECURE (NCT06927635)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Systemic therapy
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- University Health Network, Toronto